STEM-Talk

Ever since Cell Metabolism published a study that found the naturally occurring metabolite alpha-ketoglutarate reduces inflammatory signaling as well as chronic inflammation, listeners have been asking Ken and Dawn for their take on the paper. Today, we have the author of the paper, Dr. Gordon Lithgow, as our guest on STEM-Talk. We talk with Gordon in-depth about his study and the potential of alpha-ketoglutarate to have positive effects on lifespan and healthspan. Gordon is a professor and vice president of Academic Affairs at the Buck Institute in Novato, California, where his research focuses on uncovering genes and small molecules that prolong lifespan through enhanced molecular stability. Today we cover Gordon’s research into alpha-ketoglutarate in the second part of a two-part interview. In part one, episode 119, we asked Gordon about his fascination with C elegans, a microscopic worm that Gordon and other geneticists study and often use for their research. He particularly covered two of his studies involving C elgans: one that looked at the role that protein homeostasis plays in aging;  and another study that found vitamin D3 improves protein homeostasis and slows aging. A native of Scotland, Gordon researched the biology of aging at the University of Manchester in England before moving to the Buck Institute in 2000. Gordon is married to Dr. Julie Andersen, who was our guest on episodes 117 and 118 and who also is a researcher at the Buck Institute. Show notes: 00:03:20 Dawn opens part two of our interview with Gordon by mentioning his most recent paper on alpha-ketoglutarate, which has generated a lot of buzz. This study suggests there is a metabolite that one can buy in a health food store that may have a positive effect on lifespan as well as healthspan. Dawn goes on to mention that alpha-ketoglutarate (AKG), is a naturally occurring metabolite. She notes that previous studies on it have shown that blood plasma levels of AKG can drop up to 10-fold as we age. Dawn asks Gordon to explain what AKG is and how it is involved in so many of our fundamental physiological processes. 00:07:41 Ken mentions that in the study, Gordon fed the mice calcium AKG. Ken asks why Gordon chose calcium AKG as opposed to arginine AKG, which is a dietary supplement often used by athletes and bodybuilders to improve their performance and reduce muscle fatigue. 00:09:22 Dawn mentions that when Gordon’s paper came out in Cell Metabolism, Gordon was quoted as saying, “The nightmare scenario has always been life extension with no reduction in disability.” Dawn goes on to state that this study showed that the middle-aged mice who were treated got healthier over time, and that even the mice that died early saw improvements in their health. Dawn asks Gordon to elaborate on this apparent extension in healthspan. 00:12:41 Dawn asks Gordon about the significance of the finding in his study that calcium AKG reduced inflammatory signaling, as well as chronic inflammation, as it relates to degenerative aging. 00:14:57 Ken asks if Gordon’s study has been replicated in any other strains of mice. 00:18:54 Dawn mentions that Ponce De Leon Health, which is based in Florida, is marketing a formulation of calcium AKG under the brand name Rejuvant. She goes on to mention that Gordon and his colleagues at the Buck worked with Ponce De Leon Health to develop the product and that Gordon owns stock in the company. Dawn asks Gordon to give an overview of this partnership and address the concerns that some people may have about a potential conflict of interest. 00:21:17 Ken asks Gordon to explain how the dose of calcium AKG used in the mouse study compares to the dose recommended for humans via the commercial supplement, noting that the dose seems to be substantially and proportionally higher for mice. 00:22:03 Ken asks why Ponce De Leon Health is marketing different formulations of its product for men and women, and what the difference is between the two formulations. 00:24:53 Dawn asks with regard to the consistent positive longevity effects of AKG in C elegans and now mice, if these positive effects are translational to humans. 00:27:39 Ken mentions that there are several biomarkers for determining biological age, and goes on to mention that Ponce De Leon Health distributes a product called “True Age,” a test of biological age based on epigenetic markers. Ken asks if Gordon has any thoughts on this, and what biomarker does he use to evaluate biological age in his research and why. 00:31:09 Dawn mentions that an article published in the Mercury News in San Jose, Calif.,  interviewed a number of scientists who were very impressed by Gordon’s AKG study and its results. A handful of scientists, however, were quoted as saying that while “AKG is likely to be safe, it is possible there are side effects.” Dawn asks Gordon if he knows of any side effects of AKG that people need to be aware of. 00:32:37 Dawn mentions a paper published in Nature communications by Gordon and some international colleagues titled “Polyunsaturated fatty acids and p38-MAPK link metabolic reprogramming to cytoprotective gene expression during dietary restriction”which used a genetic model of dietary restriction in C elegans. Dawn goes on to mention that the paper shows that dietary restriction results in increased levels of long chain omega 6 and 3 polyunsaturated fatty acids including linoleic acid and EPA, which are known to signal increased expression of cytoprotective and detox genes that increase lifespan. Dawn asks Gordon to talk about how genetic models of dietary restriction both do and don’t reflect true dietary restriction in animal models and humans. 00:36:01 Ken follows up on the previous question by asking Gordon if he thinks that the metabolic reprogramming seen in the C elegan model gives any insight into how intakes of dietary polyunsaturated fatty acids (PUFAs) might alter health outcomes in humans. Ken goes on to mention that Gordon noted in his paper that supplementing C elegans with monounsaturated fats decreased lipid peroxidation, but exogenous fish oil both increases peroxidation and decreases lifespan. Ken notes that this seems to be in stark comparison to humans, where much time, research and money has been poured into creating various fish oil formulas to improve human health. Gordon provides his thoughts on this matter. 00:39:38 Dawn mentions that when Gordon first joined the Buck institute and started looking at aging and disease, the word geroscience did not exist. She goes on to mention that today there are hundreds of companies around the world devoting themselves to the idea of geroscience. Gordon discusses how he and his colleagues came up with this word and what it refers to. 00:42:07 Dawn says that it is an exciting time to be in the field of aging. She asks Gordon where he thinks the future of aging research is headed, and what are some questions that he and his colleagues at the Buck will be addressing in the years to come. 00:45:31 Dawn closes the interview by mentioning that Gordon’s wife, Julie Andersen (episodes 117 and 118), said Gordon was the cook in the house. Dawn goes on to note that she understands Gordon makes a turmeric curry about every week. Dawn asks if there is any special reason for this fondness of curry, and why the choice of turmeric. Links: Gordon Lithgow lab Learn more about IHMC STEM-Talk homepage Ken Ford bio Ken Ford Wikipedia page Dawn Kernagis bio  

Episode 119: Gordon Lithgow talks about the biology of aging and prolonging lifespan Our guest today is Dr. Gordon Lithgow, a professor and vice president of Academic Affairs at the Buck Institute in Novato, California. Gordon’s research focuses on uncovering genes and small molecules that prolong lifespan through enhanced molecular stability. Because our conversation with Gordon was so extensive and fascinating, we have split his interview into two parts. In today’s part one of the interview, we talk to Gordon about his background and early studies as well as his fascination with C elegans, a microscopic worm that Gordon and other geneticists study and often use for their research. We particularly talk in depth about two of Gordon’s studies involving C elgans: one that looked at the role that protein homeostasis plays in aging;  and another study that found vitamin D3 improves protein homeostasis and slows aging. A native of Scotland, Gordon researched the biology of aging at the University of Manchester in England before moving to the Buck Institute in 2000. Gordon is married to Dr. Julie Andersen, who was our guest on episodes 117 and 118 and who also is a researcher at the Buck Institute. In part two of our interview with Gordon, we talk to him about a recent study of his that found the naturally occurring metabolite alpha-ketoglutarate reduces inflammatory signaling as well as chronic inflammation. The study has generated quite a bit of buzz because it suggests there’s a readily available metabolite that may have positive effects on lifespan and health span. As a result, Ken and Dawn have been getting numerous questions from listeners about alpha-ketoglutarate and Gordon’s recent study that ran in Cell Metabolism, which Gordon talks about in depth in part two. Show notes: 00:03:59 Dawn opens the interview asking Gordon about growing up in a steelwork town outside of Glasgow, Scotland. 00:04:22 Dawn asks Gordon what he was like as a kid. 00:05:07 Dawn asks Gordon how a young boy who had aspirations of becoming a professional rugby or soccer player suddenly becomes passionate about birdwatching. 00:07:07 Gordon talks about how he went to the University of Strathclyde after high school and how he was the first in his family to attend college. 00:07:48 Dawn asks Gordon why he shifted his academic interests from microbiology to genetic engineering. 00:09:05 Ken asks what led Gordon to attend the University of Glasgow for his doctorate after getting a degree in microbiology. 00:10:04 Ken asks why Gordon went to Switzerland after receiving his doctorate. 00:10:57 Ken asks what prompted Gordon to head to Boulder, Colorado, and why he became so interested in the biology of aging. 00:12:57 Dawn mentions that while Gordon was working in Tom Johnson’s lab during his post-doc, Gordon made what Tom referred to as an amazing discovery. Gordon had found that a single heat shock to worms increased their lifespan by 15 percent. Dawn asks Gordon to talk about this discovery as well as his paper that ran in PNAS. 00:15:46 Ken mentions that because of Gordon’s discovery, many people have developed an interest in sauna. 00:16:57 Dawn mentions that a number of years after discovering that heat shocking increased the lifespan of worms, Gordon followed up on that study and demonstrated that giving the worms repeated mild hormetic heat treatments increased their lifespan even more. Dawn goes on to ask if, since this follow-up study, Gordon has a better understanding of hormesis mechanisms at the cellular and molecular level and how that might relate to the prevention and treatment of different diseases. 00:18:02 Dawn mentions that Julie Anderson, Gordon’s wife, was interviewed for STEM-Talk episodes 117 and 118. Dawn goes on to say that when she asked Julie how she and Gordon met,  Julie said, “I was having a transatlantic relationship with Gordon and we met because we’re nerds.” Dawn asks if Gordon would like to respond to this assertion that he’s a nerd, and whether it is true that he ended up at the Buck Institute on Julie’s coattails. 00:20:40 Dawn asks Gordon what are the main questions which have motivated his research. 00:23:07 Dawn mentions that in Gordon’s work he screens natural compounds like vitamins and minerals to determine if they have the potential to affect lifespan. Gordon does this by studying C elegans, tiny nematode worms that are found in rotting fruit and on the backs of snails. Dawn asks why Gordon and other geneticists are so found of using C elegans in their research. 00:25:54 Ken mentions that a lot of Gordon’s recent research with C elegans has looked at the role that protein homeostasis plays in aging. Ken asks Gordon to give an overview of the role that proteins play in determining lifespan. 00:29:07 Ken asks Gordon about his paper in Aging Cell which indicated that the accumulation of insoluble proteins with diverse functions could be a general feature of aging. The paper also showed that many hundreds, if not thousands of proteins, undergo conformational change during aging and come out of solution. Gordon explains what this conformational change is and what it means to come out of solution. 00:29:58 Dawn mentions that, as Gordon has already pointed out, we know that proteins sustain lots of damage in the normal course of metabolism. Dawn asks Gordon to discuss how he and other researchers are trying to better understand the mechanisms of normal aging that are likely to accelerate age-related pathologies and diseases. 00:32:16 Dawn asks why Gordon started looking into how excessive dietary iron affects protein homeostasis in worms. 00:35:11 Dawn asks Gordon for his thoughts on whether or not his findings on the effects of iron in worms may have some physiological relevance for humans. 00:35:42 Ken, in light of the effects iron has on health asks Gordon what effects other metals could potentially have on protein homeostasis and overall physiology. 00:37:02 Dawn shifts to talking about Gordon’s research into vitamin D. Dawn mentions that in Gordon’s interview with Rhonda Patrick, who back in 2016 was one of STEM-Talk’s first guests, appearing in episode 3, Gordon told Rhonda a story about how someone came to the office and suggested studying vitamin D, to which Gordon said “No way. There’s nothing new to learn about vitamin D.” Dawn asks what changed his mind. 00:40:55 Ken mentions that in Gordon’s study, which appeared in Cell Reports, he observed that vitamin D3 improves protein homeostasis and slows aging. Ken states that the obvious takeaway is that it is important to maintain appropriate vitamin D serum levels. He asks if Gordon was able to determine what the appropriate level is for humans. 00:44:43 Dawn asks if Gordon has looked at whether vitamin D deficiency in older adults might explain why seniors and nursing-home residents have an elevated risk when it comes to COVID-19. 00:47:35 Ken shifts to asking Gordon about some work he did a few years ago with two other labs where they dug into the issue of experimental reproducibility. Ken asks Gordon to give a brief background of this research. 00:51:08 Ken closes part one of our interview with Gordon by mentioning that reproducibility is considered a cornerstone of experimental science. Ken asks what Gordon thinks are the primary drivers of irreproducibility in science and what Gordon thinks can be done better. Links: Gordon Lithgow lab Learn more about IHMC STEM-Talk homepage Ken Ford bio Ken Ford Wikipedia page Dawn Kernagis bio  

Today we have part two of our conversation with Dr. Julie Andersen, a professor at the Buck Institute who is conducting fascinating research into the metabolite compound urolithin-A. Laboratory experiments have demonstrated urolithin-A’s ability to induce mitophagy, which is a selective recycling of mitochondria by autophagy, a process that cleans defective mitochondria and becomes less efficient during aging. Julie’s research has focused on the potential of urolithin-A to prevent and treat such diseases such as Alzheimer’s, Parkinson’s, Huntington’s and Lou Gehrig’s disease. In part one of our interview with Julie, she talked about her interest in aging and age-related diseases as well as her early studies into developing new therapeutics for neurodegeneration. Julie has been with the Buck Institute since 2000 and has published more than 170 papers. Show notes: 00:02:15 Dawn starts the second part of our interview asking Julie how the composition of bacteria in the gut affects brain function. 00:07:08 Ken asks Julie to explain what urolithin-A is, where it comes from, and why her lab and others are so interested in it. 00:10:49 Ken mentions that a study was recently published which showed that giving urolithin-A to older mice resulted in a 42 percent improvement in endurance while running compared to a control group of mice of the same age. Ken goes on to ask Julie what it is that makes urolithin-A so impactful. 00:12:43 Dawn mentions that it is known that production of urolithin-A seems to be dependent on the presence of certain gut microbes. She goes on to ask Julie what types of gut microbes are most important in the conversion of ellagic acid. 00:13:33 Ken asks if people vary in terms of how efficiently they convert ellagic acid into urolithin-A, and if so, how much variance is there. 00:14:43 Julie explains what she has learned about how to better analyze the gut microbiome composition from her studies with mice. 00:15:51 Ken asks if there is a test one can take to see if they are a urolithin-A producer. 00:16:19 Ken mentions the June 2019 paper by Chris Rinsch’s team in Nature Metabolismwhich showed a striking up-regulation of mitochondrial gene expression, including some induction of mitophagy genes in the skeletal muscle of older adults after 4 weeks of oral urolithin-A supplementation. He goes on to say that given the well-documented mitochondrial dysfunction in Parkinson’s disease, which seems to be ubiquitous, he asks what Julie’s thoughts are on the use of urolithin-A supplementation in Alzheimer’s or Parkinson’s 00:19:22 Dawn mentions that Julie wrote a paper titled “Senescence as an Amyloid Cascade: The Amyloid Senescence Hypothesis,” about the intersection of amyloid-beta oligomers and cellular senescence in Alzheimer’s disease, cautioning against completely rejecting the amyloid hypothesis. Dawn asks if the intersection of senescence with amyloid burden help to address the lack of correlation between amyloid burden and disease burden in both animal models and humans. 00:26:22 Dawn asks about the compound “C1” that Julie’s lab has demonstrated boosts autophagy and, as a result, shows promise in treating Alzheimer’s. 00:30:27 Dawn mentions Mitopure, which is a commercially available oral formulation of urolithin-A from a Swiss company called Amazentis. This product provides urolithin-A directly regardless of one’s diet or microbiome composition. Dawn goes on to ask if Julie has any thoughts on the benefits of this product. 00:32:23 Dawn asks if there is any evidence that urolithin-A taken orally can cross the blood-brain barrier to reach key target cells in the brain. 00:35:05 Dawn asks if the high concentration of peroxidation-sensitive lipids in the brain, which contribute to its sensitivity, is something that will eventually build regardless, or are there modifiable factors that can alter the susceptibility of lipid species in the brain to peroxidation. 00:36:06 Julie talks about the potential role of senolytics in the treatment of neurodegenerative disorders, and what the current barriers are to implementing them. 00:39:29 Dawn mentions that Julie has recently written about the senolytic effects of lithium. The results of this study suggested that lithium might be beneficial to COVID-19 patients. 00:31:21 Dawn asks Julie about the shift in the conversation about aging from lengthening lifespan, to increasing the quality of life, to achieve a relatively disease-free state for the longest time possible. 00:48:04 Dawn closes the interview asking Julie about using her down time during COVID to learn to play the mandolin and speak Spanish. Links: Learn more about IHMC STEM-Talk homepage Ken Ford bio Ken Ford Wikipedia page Dawn Kernagis bio

Our guest today is Dr. Julie Andersen, who is best known for her research into aging and age-related diseases. A professor at the Buck Institute Buck Institute for Research on Aging, an independent biomedical research institute that researches ways to extend the healthy years of life, Julie and her colleagues at Buck have focused on understanding the underlying age-related processes driving neurodegenerative diseases in order to identify novel therapeutics. Because our conversation with Julie was so fascinating and long, we have divided it into two parts. In today’s part one of her interview, we talk to Julie about her youth and early career. We also talk to her about the potential of of rapamycin to protect brain cells and mitochondria in a mouse model of Parkinson’s disease as well as her thoughts about the Amyloid Cascade Hypothesis. In part two, which will go live in a few weeks, we have an in-depth conversation with Julie about her research into the neuroprotective properties of urolithin A. In terms of Julie’s background, she received her Ph.D. from UCLA and did her post-doc in the department of neurology at Harvard. In 2000 Julie joined the Buck Institute. Show notes: [00:03:33] Dawn opens the interview asking if it is true that Julie was a quiet kid who normally sat in the back of the classroom. [00:03:52] Dawn mentions that Julie was born in Montana but that she grew up in northern Idaho. Dawn asks what it was that brought Julie’s family to Idaho. [00:04:29] Dawn asks Julie what interests she had growing up. [00:05:05] Ken remarks on the fact that one of Julie’s favorite books is a biography of Clementine, Winston Churchill’s wife, and asks where Julie’s interest in Clementine came from. [00:05:46] Dawn mentions that for Julie’s undergraduate degree, she went to Washington State University, where her father was a professor. Dawn asks if Julie knew from the start that she was going to focus her undergraduate studies on plant physiology. [00:07:03] Ken asks Julie took her to UCLA for her Ph.D. [00:08:16] Dawn asks Julie what led to travel across the country to Boston for her post-doc. [00:09:26] Julie explains why she eventually returned to California after her Ph.D. [00:11:32] Dawn asks Julie to tell the story of how meeting someone she described as “a fellow nerd” at an aging conference eventually led her to taking a position at the Buck Institute. [00:14:34] Ken remarks that Julie must like working at the Buck, given she has remained there for the last 20 years. Julie describes what is it about the Buck Institute that makes it such a special place. [00:17:51] Dawn mentions that for the past 20 years, Julie and her lab at Buck have looked at a lot of different aspects of neurodegeneration, with a heavier concentration on autophagy in the past five years. Dawn goes on to mention that Julie has especially been investigating a natural bioactive known as urolithin A. Before diving into all of this work specifically, Dawn asks Julie, what drew her to the study of neurodegeneration to begin with. [00:19:55] Ken asks what prompted Julie’s current focus on autophagy. [00:24:11] Dawn explains that degradation of damaged mitochondria via lysosomal autophagy is a key cellular pathway in the maintenance of mitochondrial homeostasis.  Disruption of this pathway contributes to the progressive cell loss that is associated with Parkinson’s disease. She goes on to mention that Julie published the results of a study in 2015that found rapamycin can protect brain cells and mitochondria in a mouse model of Parkinson’s disease. Julie explains the significance of this study and talks about the importance of rapamycin in the research of therapies for Parkinson’s disease. [00:30:44] Dawn asks Julie to explain the concept, and the significance of, transcription factor EB (TFEB), which is a protein that is encoded in humans by the TFEB gene, and is a master regulator of autophagy and lysosomal function. Julie explains how this has become a potential target for treating Parkinson’s and Alzheimer’s. [00:32:41:] Ken mentions that much of Julie’s work has focused on cellular senescence. Ken asks for Julie to describe the concept of senescence, as well as its impact on neurodegenerative diseases. [00:41:26] Ken mentions that exposure to the herbicide paraquat is associated with increased risk of idiopathic Parkinson’s disease. He goes on to mention that Julie published a study in 2017 that showed exposure to certain environmental toxins promotes accumulation of senescent cells in the aging brain. Julie talks about her finding that therapies targeting senescent cells may constitute a strategy for treatment of sporadic Parkinson’s disease. [00:46:47] Dawn ends part one of the interview by mentioning that Julie followed up her 2017 study with another study that examined whether one could screen known neurotoxicants for their ability to cause astrocytes, which are a mitotic-cell type in the brain important for maintaining neuronal health, to undergo senescence. Julie ends the interview with a discussion about the study, titled “Screening Method for Identifying Toxicants Capable of Inducing Astrocyte Senescence.” Links: Learn more about IHMC STEM-Talk homepage Ken Ford bio Ken Ford Wikipedia page Dawn Kernagis bio      

Our guest today is Dr. Marcas Bamman, an internationally recognized researcher known for his scientific contributions to the biology of human skeletal muscle and medical rehabilitation. Marcas recently joined IHMC as a Senior Research Scientist. He is the founder and former director of the University of Alabama at Birmingham Center for Exercise Medicine. Marcas and the UAB center are recognized as world leaders in the biological mechanisms underlying exercise-induced adaptations and their clinical utility in disease prevention, treatment and rehabilitation. At IHMC, he will expand his research aimed at maximizing the performance and resilience of elite warfighters. One of Marcas’ first projects at IHMC is working with the institute’s Chief Science Officer Tim Broderick on a DARPA-sponsored program. This research is aimed at developing a revolutionary platform to enhance training and resilience of elite service members. Tim talked about the program, called the Peerless Operator Biologic Aptitude project, during his interview on episode 112 of STEM-Talk. In today’s interview, we talk to Marcas about the Peerless project as well as his earlier research into the many ways that exercise and strength training can induce a multitude of health benefits. Show notes: [00:03:11] Dawn opens the interview by asking Marcas where he grew up. [00:03:21] Dawn asks Marcas what sports he played given that he is now an exercise scientist. [00:03:45] Dawn mentions that in addition to being good at basketball and soccer in high school, that Marcas was also good in his chemistry and mathematics classes. [00:04:47] Dawn asks if it is true that Marcas was the sports editor of his high school newspaper. [00:05:25] Dawn asks Marcas why he decided to pursue science despite having a promising future as a sportswriter. [00:06:08] Ken asks if Marcas decided to attend Kansas State University after high school because it was the same school his father had attended. [00:06:59] Ken asks what led Marcus to the University of Alabama Birmingham for his master’s degree. [00:08:09] Dawn asks if it is true that Marcas met his wife Deanna in a fitness center. [00:09:00] Marcas explains the non-traditional rout he took to earning his doctorate at the University of Florida. [00:14:05] Dawn mentions that while Marcas was working at NASA, he worked on a study that had people go through 14 days of bedrest in an effort to mimic space flight. The resulting paper appeared in Medicine and Science in Sports and Exercise and was titled, “Resistance Exercise Prevents Plantar Flexor Deconditioning During Bed Rest.” Dawn asks about the study and its findings, as well as how Marcas was able to convince people to spend 14 days in bed. [00:19:47] Marcas explains how he ended up back at UAB following his dissertation. [00:20:32] Ken asks what Marcas’ overarching question was that drove his research when he began his career at UAB. [00:22:24] Dawn mentions that Marcas has played a major role nationally in the recognition and growth of exercise medicine. Dawn asks how Marcas first became interested in this concept of exercise as medicine. [00:24:06] Dawn asks Marcas to talk about his research that has shown that exercise can help prevent and delay health problems, and that different types of exercise can bring about different health benefits. [00:29:38] Dawn mentions that in 2011 Marcas established the University of Alabama Birmingham Center for Exercise Medicine (UCEM), which has become well known nationally as a leader in exercise medicine. Marcas gives an overview of how the center came about and the research that is conducted there. [00:34:23] Marcas gives an overview of a clinical trial he conducted in 2011 which showed that men and women in their 60’s and 70’s who underwent supervised weight training developed muscles that were as large and strong as those of the average, untrained 35- to 40-year-old. [00:37:34] Dawn asks if there is any evidence suggesting that male and female older adults need different types of exercise training for maximal health benefits. [00:40:06] Ken asks Marcas about his research into how a person’s genetic background determines their response to exercise, which helps explain why some individuals are more naturally suited to one type of exercise over another. [00:44:42] Marcas shares that while some people may not gain as much muscle from exercise as others, everyone responds in a positive way to exercise. [00:45:56] Dawn asks if Marcas thinks there will ever be a drug developed that will give people the same kind of benefits as exercise. [00:47:12] Ken mentions that there have been some drug trials that have shown an ability to increase muscle size in older adults. He goes on to mention that these changes have not translated into functional outcomes or patient benefits. He asks if there might be a sweet-spot for people who are limited in the amount of exercise they are able to do to maximize the benefits of minimal exercise with one of these drugs. [00:48:35] Ken mentions that PPAR-delta agonists have shown substantial promise for specific populations. [00:50:10] Ken explains that there are studies suggesting that exercise can help prevent or delay the onset of Alzheimer’s. He goes on to ask, in light of all the many benefits of exercise, why doctors are not prescribing exercise as a treatment rather than merely writing drug prescriptions. [00:54:05] Dawn asks if the American Heart Association’s recommendations that people get at least 150 minutes of moderate to vigorous physical activity a week (including two days a week of moderate to high-intensity strength training) falls in line with what Marcas would recommend. [00:56:11] Dawn mentions that in 2017 Marcas published a paper looking into the dose-response effects of exercise in older individuals. Dawn asks if Marcas can elaborate on this paper and explain whether he thinks establishing an effective dose of exercise might have both scientific and practical merit. [01:01:21] Dawn explains that due to COVID-19 many people are avoiding gyms. She asks if Marcas has any recommendations for people who are struggling to keep their muscles in shape during this pandemic. [01:03:31] Ken explains that sedentary adults can lose 30 to 40 percent of the total number of fibers in their muscles by the time they are 55. This is significant because many neuromuscular and chronic inflammatory diseases are closely associated with muscle weakness, skeletal muscle atrophy, and muscle fatigue. It’s a serious issue, and one of the reasons that the NIH launched a six-year, $200-million-plus study called the NIH Molecular Transducers of Physical Activity Consortium which is targeting an enrollment of about 2,000 sedentary people and 300 highly active/trained people.  Ken asks Marcas, as a part of this ambitious study, to give an overview as to how the study is being conducted and what researchers hope to learn. [01:07:49] Dawn mentions that even though the merits of exercise are well known, the biggest difficulty is getting people to maintain a healthy exercise regimen. She asks for Marcas’ opinion in regards to the balance between applied and basic science from a funding point of view and how to best maximize solving the problems associated with a lack of exercise. [01:10:18] Dawn mentions that Parkinson’s disease is the most common motor neurodegenerative disease. She goes on to mention that Marcas, earlier this year, had a paper in Frontiers in Physiology about a study that set out to identify transcriptional networks that may contribute to resistance-training-induced neuromuscular remodeling in Parkinson’s disease. Dawn also asks about Marcas’ 2014 paper that found high intensity exercise improved muscle mass, mitochondrial function and physical capacity in people with Parkinson’s. [01:15:09] Dawn mentions that with Marcas’ move to IHMC, he is transitioning from clinical populations to now working on Department of Defense-focused work. She points out that he will be taking the same sorts of questions and principles he once explored with clinical populations and now attempt to apply them to other areas. Marcas explains this transition. [01:16:58] Marcas talks about his reasons for leaving his well-established lab at UAB and coming to IHMC. [01:18:51] Ken mentions that one of Marcas’ first projects at IHMC is a DARPA-sponsored program aimed at developing a revolutionary platform to enhance training and resilience of elite service members known as the Peerless Operator Biologic Aptitude project. Marcas gives an overview of this project and his role in it. [01:22:09] Marcas talks about his recent experience taking a building on an Air Force base in San Antonio and converting it into a human-performance lab for the Peerless project. [01:24:06] Ken harkens back to Marcas’ aforementioned 2011 paper examining the adaptation in older individuals to resistance training. Ken asks in regards to this if the study looked at muscle power, which he says seems to be the worst of the muscular-function declines in older adults. [01:26:44] Dawn asks about another project that Marcas is working on, which is being sponsored by the Office of Naval Research and is called Precision High-Intensity Training Through Epigenetics, or PHITE. Dawn explains that this trial is trying to determine if the effect of exercise dose on performance optimization and the underlying molecular mechanisms of that phenomenon with a focus on epigenetics. [01:30:43] Marcas tells an interesting story about his experience of zero gravity back when he worked at NASA. [01:32:53] Marcas explains what his exercise routine consists of. [01:34:08] Dawn asks Marcas what sort of diet he follows. [01:36:14] Ken closes the interview asking Marcas about the things he likes to do when he is able to find some spare time in his busy schedule. Links: Learn more about IHMC STEM-Talk homepage Ken Ford bio Dawn Kernagis bio Marcas Bamman bio

It’s that time again for another Ask Me Anything episode. And we must say, listeners sent us a wealth of excellent questions for this round of Ask Me Anything. In today’s podcast, Ken and Dawn answer questions that range from blood-flow restriction to swimming induced pulmonary edema to intermittent fasting to methylene blue to low-carb diets, and much, much more. If you have questions you want to send to Ken and Dawn for an Ask Me Anything episode, email your question to STEM-Talk Producer Randy Hammer at rhammer@ihmc.org. Show notes:  [00:02:24] In light of Ken’s former experience in wrestling, a listener asks about wrestlers who perform neck bridges to strengthen their neck.  The listener wonders if Ken thinks neck exercises are important and, if so, what does he does in that regard. In his response, Ken mentions a neck-strengthening device, Iron Neck. [00:06:12] A listener asks Ken and Dawn about their morning routines and what scientific journals they read and if they could each give a few book recommendations. [00:08:16] A listener asks Dawn, in light of her accepting a position at the University of North Carolina, if she will continue working with IHMC and  co-hosting STEM-Talk. [00:09:13] A listener asks if and how Dawn sees crossover between the research on humans in extreme environments that she did at IHMC, and the clinically oriented work she is doing now. [00:10:37] A listener mentions that they have recently started using blood-flow restriction training in their workouts thanks to STEM-Talk and have enjoyed the experience. The listener goes on to mention, however, that they are noticing they feel light headed when going for a run after a blood-flow restriction resistance workout. The listener asks Ken if he has any knowledge of this phenomenon, or other side effects of blood flow restriction exercise. [00:12:56] A listener mentions that they have just finished reading Denise Minger’s “Death by Food Pyramid” which explains that no nutrition-oriented classes are required for a Harvard medical degree, which is also true of about 70% of medical schools in the nation. The listener goes on to mention, from their own experience, that people are often told to consult their doctor when thinking about the potential benefits of new diets. Doctors and even nutritionists, however, generally prescribe the Mediterranean diet and do not seem to know much about low-carb diets. The listener asks Ken who one should consult when wanting to start a ketogenic diet. In his response, Ken mentions several resources, including the websites Virta Health and Diet Doctor; and the books “The Art and Science of Low Carbohydrate Living” as well as “The Art and Science of Low Carbohydrate Performance.” [00:15:22] A listener, who is a triathlete, asks Dawn for advice about performance in extreme environments, particularly in regards to swimming induced pulmonary edema. They also go on to ask about Dawn’s thoughts on Sildenafil, also known as Viagra. In her response, Dawn mentions a paper by Dr. Richard Moon of Duke University, “Swimming-Induced Pulmonary Edema: Pathophysiology and Risk Reduction with Sildenafil.” [00:20:08] A listener asks Ken a question about an article they read about a study out of the University of Glasgow that was published in Nature Scientific Reports. The listener highlights a quote from the press release announcing the publication of the article: “There is no magic diet, or magic food, for weight control. Instead, people have to find the best way to eat fewer calories. Low-carb diets have had a lot of hype from media and celebrities, but they are no better than high-carb diets. Their evidence is generally poor, and our earlier research found low-carb diets are associated with some vitamin deficiencies, with more diabetes, not less. We can’t stop people cutting carbohydrate, and it may suit some people at least in the short-term, but there should be a health warning.” The listener goes on to ask Ken if it is indeed true that contrary to the article, there is, in fact, a growing body of evidence in support of low carb diets. [00:22:55] A listener writes to Ken saying that they have read a lot about the 5:2 Diet, and the neuroprotective and longevity benefits it has in mice. They go on to ask Ken if there are any studies showing similar benefits in humans. Ken mentions that there are indeed studies in the works on intermittent fasting. He also recommends that for those listeners who are interested in intermittent fasting to check out three STEM-Talk episodes: Mark Mattson, episode 7; Steve Anton, episode 68; and Satchin Panda, episode 79. [00:26:22] Ken follows up with the previous question, mentioning that several listeners have asked about a recent study published in JAMA titled: “Effects of Time Restricted Eating on Weight Loss and Other Metabolic Parameters in Women and Men with Overweight and Obesity.” [00:28:52] A listener mentions that they have a friend who was just diagnosed with type-2 diabetes and who was prescribed a “Mediterranean Diet” by their doctor. The listener goes on to mention that they encouraged their friend to listen to Episode 43 of STEM-Talk with Jeff Volek, as well as to check out VIRTA Health. The listener asks Ken to give an update on how Jeff is doing, and if there is a possibility of a second interview with him on STEM-Talk. [00:31:59] A listener asks about erythropoietin, or EPO, which has been shown to promote the formation of red blood cells by the bone marrow, and has been used as a performance enhancer drug by athletes as well as an “anti-aging” drug by older people. Ken gives his take on this drug and its applications. He also shares his thoughts on anti-aging, a term he isn’t fond of. [00:35:57] Ken is asked a follow-up question about his knowledge about intermittent hypoxic training. [00:37:40] A listener asks about Ken’s experience with methylene blue, which was the topic our two-part interview with Dr. Francisco Gonzalez-Lima, episode 106 and episode 107. Ken mentions that he will include links to two methylene blue products, one from Mitolab, the other from Troscriptions TX. [00:40:54] A listener shares their experience on the ketogenic diet and says they found that they are a “hyper responder” to ketosis,  which in part means that their cholesterol numbers spike. The listener, who has since shifted to a low-carb diet but not ketogenic diet, asks Ken for thoughts on hyper-responders which might mitigate negative cholesterol numbers or if cycling on and off ketosis might work. In his answer on the research and science behind hyper responders, Ken mentions a study by Jeff Volex and his colleagues – “Paradox of hypercholesterolaemia in highly trained, keto-adapted athletes” – which reported an increased incidence of greatly elevated cholesterol in keto-adapted ultra-endurance athletes. Ken also mentions another study that just came out: “Saturated Fats and Health: A Reassessment and Proposal for Food-Based Recommendations.” [00:52:26] A listener mentions that the trajectory between Earth and Mars will next be the closest in 2033. They ask Ken, with his connections to NASA, if he thinks that a mission to Mars in 2033 is likely, and what are the potential commercial benefits of going to Mars. [01:00:48] Dawn congratulates Ken on his recent recognition as a “Florida Living Legend.”After congratulating him on this achievement, she asks him to explain a little bit about this award. Links: Learn more about IHMC STEM-Talk homepage  Ken Ford bio Dawn Kernagis bio  

Our guest today is Dr. Lilianne Mujica Parodi, the director of the Laboratory for Computational Neurodiagnostics at Stony Brook University. We will be talking to Lily about her paper in PNAS last year that revealed neurobiological changes associated with aging can be seen in a person’s late 40s, a much younger age than what was previously thought.  She and her colleagues at Stony Brook also found that this process may be prevented or even reversed based on dietary changes that involve minimizing the consumption of simple carbohydrates. The study’s targeted experiments  showed that the biomarker for brain aging could be reliably modulated with consumption of different fuel sources. The study showed that decreasing  glucose and increasing ketones resulted in the stability of brain networks. Much of Lily’s work over the years has been focused on developing neuroimaging tools. In today’s interview, we talk to her about functional magnetic resonance imaging, also known as fMRI, which measures the small changes in blood flow that occur with brain activity. It may be used to examine the brain’s functional anatomy, evaluate the effects of stroke or other disease, and even guide brain treatment. Functional magnetic resonance imaging also can detect abnormalities within the brain that cannot be found with other imaging techniques. Show notes: [00:03:08] Dawn opens the interview asking Lily what she was like as a child. [00:04:20] Dawn mentions that Lily grew up in Maryland near the National Institute of Health. Lily talks about her experiences interning at the NIH in her senior year of high school. [00:09:41] Dawn asks what brought Lily to Georgetown University. [00:10:29] Ken asks about Lily’s experience at Georgetown University, where she majored in physics and philosophy. [00:15:16] Lily explains why she went to Columbia University after graduating from Georgetown. [00:19:14] Dawn asks about Lily’s research that led to her receiving the Brain and Behavior Research Foundation Young Investigator Award in 2000. [00:22:44] Dawn asks about Lily’s experience giving a lecture at the NIH while she was wrapping up her doctorate at Columbia. [00:27:00] Dawn asks what brought Lily to Stony Brook. [00:30:30] Ken asks Lily what attracted her to biomedical engineering. [00:32:58] Dawn mentions that much of Lily’s work at Stony Brook has been focused on developing neuroimaging tools. Dawn goes on to ask why neuroimaging has not provided the anticipated success for psychiatry and neurology that the electrocardiogram provided for cardiovascular medicine. [00:39:04] Ken mentions that Lily is the director of the Laboratory for Computational Neurodiagnostics. Lily gives an overview of the lab and the research conducted there. [00:44:00] Dawn mentions that Functional Magnetic Resonance Imaging, also known as fMRI, measures small changes in blood flow that occur with brain activity, and can be used to examine the brain’s functional anatomy, and evaluate various insults, diseases, and abnormalities, that cannot be found with other imagining techniques. Dawn asks Lily to explain the technology of fMRI and its various applications. [00:45:59] Ken asks about Lily’s 2016 paper published in the Frontiers of Neuroscience journal, that ran under the title, “Signal Fluctuation Sensitivity: An Improved Metric for Optimizing Detection of Resting-State fMRI Networks.” [00:49:36] Lily discusses her lab’s involvement in the development of a technology called “Near-Infrared Spectroscopy,” which is an attempt to replicate MRI-type imaging in an ambulatory environment such as an emergency room or a rural environment. [00:51:36] Dawn asks what led Lily to start researching diets and particularly the ketogenic diet. [00:56:59] Ken mentions that there are two key factors linked to age-based cognitive impairment, those being: insulin resistance and glucose hypometabolism. Lily explains how these two phenomena affect the brain. [00:59:33] Ken asks about Lily’s 2019 paper in PNAS, titled, “Diet Modulates Brain Network Stability, A Biomarker for Brain Aging, in Young Adults.” Lily explains how this study was conducted and what its results were. [01:05:53] Dawn mentions that there have been studies showing that ketones provide greater energy to cells than glucose, even when the fuels are calorically matched. Ketones also have been shown to benefit cardiovascular health. Dawn asks Lily to explain how her study and experiments provided the first evidence for equivalent benefits in the brain. [01:09:22] Ken asks about the better-known structural MRI measures of brain age, such as declining hippocampal size. [01:14:16] Ken asks what the response to Lily’s aforementioned paper has been. [01:16:31] Dawn asks Lily what her diet looks like. [01:17:04] Dawn follows up asking Lily about her exercise routine. [01:18:08] The interview ends with Dawn asking Lily how she spends her spare time.  

Today’s interview features Dr. Peter Pirolli, a colleague and senior research scientist here at IHMC since 2017.  He previously was a fellow at the Palo Alto Research Center (PARC) and is known for his research into human information interaction. Peter’s work on information foraging theory led to his book “Information Foraging Theory: Adaptive Interaction with Information.” Peter received his doctorate in cognitive psychology from Carnegie Mellon University in 1985 and throughout his career his research has involved a mix of cognitive science, artificial intelligence, and human-computer interaction. His current interests include disruptive mobile-health technologies for precision behavioral medicine to support healthy behavior. Right now, Peter is working closely with IHMC’s Chief Science Officer Tim Broderick on a DARPA project that Tim discussed in his recent STEM-Talk interview, episode 112. Peter also talks about the project and the work that he, Tim and others at IHMC are doing to increase the biologic aptitude of elite warfighters. In today’s interview, Peter also discusses his role as the principal investigator of a project that the National Science Foundation recently awarded to IHMC. Peter and his colleagues will be working on improving epidemiological models that will be able to more accurately forecast the rate of infections and deaths related to COVID-19. Show notes: [00:02:42] Dawn opens the interview by quizzing Peter about how he took up surfing at the age of 40. [00:05:48] Ken mentions that Peter grew up in Canada, but that his father, who is Italian, decided to move the family to Italy when Peter was 8 years old. Peter discusses what that was like. [00:08:37] Dawn mentions that Peter liked to go camping and canoeing as a kid, and developed a love for astronomy. Dawn asks if it is true that Peter used to keep NASA scrapbooks. [00:10:52] Peter tells the story of the role his mother played in his decision to go to Trent University in Ontario. [00:12:45] Dawn asks why Peter decided to major in psychology and anthropology despite his childhood fascination with astronomy. [00:14:47] Dawn asks what attracted Peter to Pittsburg and Carnegie Mellon University for graduate school. [00:16:12] Ken mentions that at Carnegie Mellon, Peter had the opportunity to meet and work with Herb Simon and Alan Newell, who back in the 1950s were the early pioneers of artificial intelligence. They won the Turing Award in 1975 for their contributions to artificial intelligence and the psychology of human cognition. Ken goes on to mention that Simon also won the Nobel Prize in Economics in 1978.  Ken asks how Peter, with a background in psychology and anthropology, got to work with these pioneers of the field of AI. [00:17:59] Ken mentions that one of his favorite works from Simon and Newell was their physical symbols concept and the papers that arose from that. [00:19:54] Ken mentions that Simon and Newell were interested in developing computational models that could mimic and simulate what the human mind was doing. In addition to AI, they also conducted research that looked at information processing, decision-making, problem-solving, organization theory and complex systems. Ken asks Peter how working with these pioneers influence his later research and career. [00:22:57] Ken asks Peter to elaborate on the concept that Simon introduced known as “satisficing.” It’s a concept credited with revolutionizing economics by introducing the idea of “bounded rationality” where people have limited time and resources with which to gather data to draw their conclusions, as opposed to the “rational man” concept which assumes that a person making a decision uses all conceivably relevant information to inform their decisions. [00:25:54] Dawn mentions that in Peter’s time at CMU, he became interested in building artificial intelligence systems to tutor people one on one. Peter elaborates on this work and explains how it led him to travel across the country to work in Berkeley, California. [00:28:42] Ken mentions that Peter is particularly well-known for developing the concept of “information foraging” with Stuart Card in the late 1990’s. The concept was inspired by animal behavior theories and how animals forage for food. [00:33:42] Dawn explains that Peter’s work on information foraging led him to write his book “Information Foraging Theory: Adaptive Interaction with Information.” Dawn goes on to ask Peter about the concept of “high information scent” and what the significance of that is. [00:36:35] Dawn asks Peter to give an overview of his book which is aimed at an interdisciplinary audience. [00:39:10] Ken asks about Peter’s concept of “cooperative information foraging.” [00:41:33] Dawn mentions that the emergence of smartphones as a ubiquitous device led Peter to become interested in the possibilities of using them to support behavioral change in people. Dawn asks Peter to discuss the research he is conducting on ways to use smartphones to support health and lifestyle changes as well as alter habits. [00:44:28] Dawn shares her thoughts about how it is more effective to do this sort of research in the real world rather than studying people in a laboratory environment. [00:45:46] Dawn then mentions that one of the primary reasons that scientists study people in a lab is to control outside variables that could potentially influence or bias outcomes. She asks Peter how he studies people in the field and integrates these outside variables in his analysis. [00:47:19] Ken mentions that after knowing Peter for decades and admiring his work, Ken was able to convince Peter to join IHMC in 2017 as a senior research scientist. Peter explains what attracted him to IHMC. [00:50:17] Dawn mentions that Tim Broderick, who is the chief science officer here at IHMC, was just on STEM-Talk and discussed the interdisciplinary research team that he has put together for the Peerless Operator Biologic Aptitude project, otherwise known as PEERLESS. Dawn mentions that Peter is a key player in PEERLESS, which is a project designed to increase the biologic aptitude of warfighters so that they can increase their adaptability and resilience in extreme conditions. Peter discusses the project as well as his role in it. [00:54:09] Ken mentions that Peter became the principal investigator of a project related to COVID-19 that was just recently awarded to IHMC by the National Science Foundation. Ken asks Peter about the project, which will be working on improving epidemiological models that forecast the rate of infections and deaths related to COVID-19. [00:59:12] Dawn mentions that she has heard Peter talk about his belief that his interdisciplinary background is responsible for the productivity and success he has had throughout his career. Dawn asks Peter to talk about the importance of an interdisciplinary background in an academic world that insists on specialization. [01:02:17] Ken asks Peter to give his advice for young scientists currently attending college. [01:04:39] Peter tells the story of how he almost drowned as a result of hypothermia while surfing. [01:09:43] Ken asks about the quote Peter has on his website from Cormac McCarthy’s book “the road.” [01:13:46] Dawn mentions that she understands Peter has recently been reading William Gibson’s books and asks if Peter believes that the idea of uploading our minds to the cloud is possible or just science fiction. [01:15:17] Dawn closes the interview mentioning a photo on Peter’s website of him on a paddleboard with his dog Jake, and asks if Jake enjoys paddle-boarding as much as he looks like he does in the photo.

Our guest today is Dr. Tim Broderick, the chief science officer here at IHMC. Tim is a surgeon and biomedical scientist who joined IHMC last year. Tim has had a fascinating career as a researcher, surgeon and aquanaut. He is well-known as a pioneer in laparoscopic, robotic and telerobotic surgery. He also has led multiple ground, flight and undersea-based biomedical research projects. As a result, he is an honorary NASA flight surgeon and a NOAA undersea saturation diver. Tim spent four years as a DARPA program manager where he conceived and established five high-impact biotechnology projects that included revolutionary programs focused on precision diagnosis and treatment of military-relevant diseases and injuries. Over the years, he  has developed a substantial portfolio of cutting-edge Department of Defense research. In today’s interview, Tim gives an  overview of a fascinating project, called Peerless Operator Biologic Aptitude, which he and his colleagues at IHMC are currently working on. Show notes: [00:03:09] Dawn opens the interview asking Tim about growing up in in Cincinnati and going to Cincinnati Reds games in the 1970s with his family. [00:04:59] Ken asks if growing up in the Apollo era and witnessing the moon landing as a child influenced his interest in science and space. [00:06:16] Tim recounts a story about his father saving someone’s life at church when Tim was a child and how that had a profound impact on him. [00:07:13] Tim tells another story from his college days when he saved a man who nearly had his arm chopped off by a machete. [00:11:22] Dawn asks if it is true that as a teenager Tim would regularly dress up as Scooby-Doo. {00:13:39] Dawn asks if Tim always knew he wanted to be a doctor since he grew up in a family full of doctors. [00:15:21] Ken asks why Tim decided to attend Xavier University in Cincinnati. [00:16:41] Dawn mentions that she has rarely heard of someone heading off to college with the idea of double majoring in chemistry and computer science, and asks how that came about. [00:21:17] Dawn mentions that Tim graduated in four years and in 1986 decided to stay in town for medical school at the University of Cincinnati College of Medicine. Dawn asks what drew him there. [00:22:58] Ken asks if Tim knew he wanted to become a surgeon when he started med school. [00:26:37] Dawn asks what lead Tim to go to Richmond, Virginia, for his residency as a surgical resident at the Medical College of Virginia. [00:28:23] Dawn asks about how Tim’s interest in minimally invasive surgery during his residency, which led to him becoming the director of surgical research at VCU’s Minimally Invasive Surgery Center. [00:29:32] Ken mentions that while Tim was working at VCU he became a consulting surgeon for telemedicine and robotics for the NASA Medical Informatics Technology Applications Consortium. Ken asks what that work entailed. [00:32:32] Ken asks about Tim’s early work in laparoscopic robotic and telerobotic surgery. [00:38:00] Ken asks about how Tim’s experience in remote surgery for astronauts led him to become an aquanaut and a crew member for NASA’s NEEMO 9. [00:40:24] Dawn mentions that it was Tim’s support that was one of the reasons that Dawn had the chance to join NEEMO as a crew member. She goes on to mention that Tim logged time underwater as a NEEMO aquanaut when he returned to the project several years after NEEMO 9 for NEEMO 12. Tim describes what his research was focused on for that mission. [00:43:33] Dawn notes the similarities between an operational environment such as NEEMO, spaceflight and the operating room. Dawn asks if Tim’s experiences in the operating room crossed over into his work on the NEEMO mission. [00:45:08] Tim shares some of his favorite memories from his time underwater with NEEMO. [00:49:48] Dawn mentions that beginning in the year 2003, Tim spent seven years as a senior scientist and trauma portfolio manager for the US Army Medical Research and Material Command Telemedicine and Advanced Technology Research Center. Tim describes the work he did during this period. [00:50:49] Dawn asks about Tim’s time as a program manager for DARPA, specifically about his development of biocompatible nanoplatforms that enabled in vivo diagnostics. [00:55:55] Ken ask about Tim’s development of modular therapeutic nanotechnologies that permit flexible targeting of tissues for improved treatment of diseases such as antibiotic resistant bacterial infections and traumatic brain injury. [00:59:29] Dawn asks how Tim ended up becoming the chief science officer at the Wright State Research Institute after his work at DARPA. [01:00:17] Dawn mentions that what she likes most about Tim’s work is its focus on direct development of solutions for the end-user, similar to what is done at IHMC. Dawn asks how this type of work differs from basic science, and what drew Tim to this sort of research. [01:03:10] Ken mentions that prior to joining IHMC, Tim collaborated with IHMC on a project called PHITE for short. Tim expands on this multi-institutional effort and explains its goals and methods. [01:06:30] Ken talks about how last year Tim came to IHMC as chief science officer and a senior research scientist. [01:09:01] Dawn explains that Tim has assembled an interdisciplinary research team at IHMC to develop science and technology with the aim of raising the performance of elite warfighters in roles such as special operations and fighter pilots. She asks about a project called Peerless Operator Biological Aptitude, or PEERLESS for short. Tim discusses how this project is being designed to increase the biological aptitude of warfighters so that they can increase their adaptability and resilience in extreme conditions. [01:13:43] Ken mentions that another important aim of PEERLESS is to develop science and technology that might contribute to extending the career of warfighters in the special-operations community, and asks Tim to elaborate on this concept. [01:15:30] Tim talks about the stellar team he has put together including not only IHMC researchers but other organizations as well. [01:18:20] Tim explains that when he wants to take some time to get away, he likes to spend time at the beach with his family. [01:18:54] Dawn ends the interview mentioning that Tim also enjoys listening to classical music and asks if it is true that he has three daughters who play the violin. Links: Learn more about IHMC STEM-Talk homepage Tim Broderick bio Ken Ford bio Dawn Kernagis bio  

Today we have the second of our two-part interview with Dr. Tommy Wood. Ken and Dawn talk to Tommy about his ongoing research into lifestyle approaches that can improve people’s health span, lifespan and physical performance. Tommy also talks about the physiological and metabolic responses to brain injury and how these injuries can have long-term effects on brain health. In part one of our interview, episode 110, Tommy shared his thoughts on the research he has done on the importance of metabolic health as a way to for people to protect themselves from COVID-19. Tommy also talked about his work on developing accessible methods to track human health and longevity and his research on ways to increase the resilience of developing brains. Tommy is a UK-trained physician who is also a colleague of ours here at IHMC. In addition to being a research assistant professor of pediatrics at the University of Washington  in the division of neonatology, Tommy occasionally spends time at IHMC as a visiting research assistant. For a more detailed explanation of Tommy’s background, check out the introduction to part one of our interview, episode 110. We also recommend checking out Tommy’s earlier appearances on STEM-Talk, episodes 47 and 48. Show notes: [00:02:50] Dawn continues our interview with Tommy asking why some people refer to Alzheimer’s as type-3 diabetes. [00:05:00] Dawn refers to a chart that Tommy incorporated into his IHMC lecture in February of this year, which was part of a paper that showed how glucose responds with age. Dawn asks Tommy to walk listeners through what the chart details. [00:06:38] Dawn asks if Tommy agrees with Art De Vany, who in his most recent appearance on STEM-Talk, said that insulin resistance is associated with nearly every major disease that people worry about today. [00:07:38] Tommy talks about the mean amplitude of glycemic excursions and how this is the best predictor of cognitive functions. [00:09:31] Dawn asks about the waffle/fast-food study, and what the results of that paper mean for the effect of the modern American diet on health and cognitive ability. [00:11:00] Dawn asks about the effects of stress on memory and mood. [00:13:39] Dawn posits that we see many a public-service announcement about the dangers of smoking and alcohol consumption, and asks if the case could be made that we should also have public service announcements about the dangers of high blood sugar, as it is even more of a public-health issue than smoking and alcohol consumption. [00:15:42] Tommy transitions to talking about the importance of sleep in regards to brain health. [00:17:01] Ken mentions that in response to the common advice of getting eight hours of sleep, Tommy has made the point that perhaps more important than the number of hours is the quality of those hours of sleep. [00:20:15] Dawn asks Tommy about the use of Tylenol PM, or Ambien before bed for those people who have difficulty getting to, or staying, asleep. [00:22:07] Ken asks if it is true that muscle mass and body composition are exceptionally important in regards to brain robusticity. [00:24:43] Ken asks about Tommy’s favorite paper, “1,026 Experimental Treatments in Acute Stroke,” and why he loves this paper so much. [00:27:31] Tommy gives an overview of what happens as a result of an acute brain injury across the lifespan. [00:29:35] Tommy discusses Creatine, which is a compound derived from amino acids that has been shown to be effective in treating brain injuries. [00:32:56] Dawn asks Tommy what he has learned in terms of the overall therapeutic effects of ketones. [00:40:20] Dawn asks what would be one question that Tommy wishes health experts contemplated more often, in terms of health span, and what would be his answer to said question. [00:42:35] Dawn mentions that Tommy has done a lot of work helping individuals overcome chronic health conditions, and has thought about ways to scale these processes using digital means. Tommy gives advice to people seeking to develop scalable solutions designed to engineer sustained health. [00:45:33] Ken mentions that Tommy espouses an “ancestral” approach to supporting health, referring to the diet and lifestyle of our Paleolithic ancestors, and the influence that geography had on these factors for various populations of ancient people. Ken asks if there is reason to think that genetics influence the relative importance of animal foods and plant foods for brain health. [00:49:30] Dawn asks if the effects that animal husbandry has on climate change, which can contribute negatively on our health, outweigh the benefits that consuming animal products have for our health. [00:52:42] Dawn asks if there are any plant foods that support our brain health. [00:57:05] In regards to pro-longevity pharmaceuticals, which have not been very fruitful, Dawn asks if Tommy thinks that there are other factors regarding diet and lifestyle that can boost the healthspan more, and that people should be paying closer attention to, rather than waiting for a drug to extend their longevity. [01:00:53] Ken asks if Tommy has changed his thinking with respect to lifestyle determinants of health since his first appearance on STEM-Talk. [01:02:54] Ken brings up that Tommy often talks about the fact that the brain is capable of repairing itself and even growing as we age, but in order to do this it requires stimulation. Ken asks what are the best ways for people to stimulate their brains. [01:05:27] Dawn asks Tommy to explain why learning to walk is, cognitively speaking, more difficult than learning biochemistry, and how this relates to the demand-driven decline theory, as well as the grandmother hypothesis. [01:09:28] Dawn asks if Tommy is on his way to becoming a barbecue master, given his wife’s praises about his cooking. [01:10:38] Ken asks if Tommy ever craves fish and chips. [01:11:52] Dawn asks how Elizabeth is doing, now that she and Tommy share a home with two boxers. [01:14:05] Dawn mentions that a little birdy told us that in Tommy’s medical school yearbook, each person was assigned with a fictional disease, and that Tommy’s was the acronym SHHH. Dawn asks what SHHH stands for and if Tommy has changed at all since then. Links: Tommy Wood bio Tommy Wood Researchgate bio Two new papers by Tommy Wood: Variability and sex-dependence of hypothermic neuroprotection in a rat model of neonatal hypoxic–ischaemic brain injury The Future of Shift Work: Circadian Biology Meets Personalised Medicine and Behavioural Science Learn more about IHMC STEM-Talk homepage Ken Ford bio Dawn Kernagis bio